At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer
A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial shows TAMP-delivered gemcitabine significantly lowers systemic exposure compared to standard IV delivery in locally advanced pancreatic cancer.